Holen Sie sich die Stockscreener-App
4.29
0.23%
-0.010
Vorhandelsmarkt:
4.21
-0.08
-1.86%
Schlusskurs vom Vortag:
$4.30
Offen:
$4.24
24-Stunden-Volumen:
520.29K
Relative Volume:
0.93
Marktkapitalisierung:
$90.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-94.11M
KGV:
-0.7138
EPS:
-6.01
Netto-Cashflow:
$-86.06M
1W Leistung:
+1.18%
1M Leistung:
-20.41%
6M Leistung:
+22.92%
1J Leistung:
-42.11%
1-Tages-Spanne:
$4.24
$4.325
1-Wochen-Bereich:
$4.14
$4.34
52-Wochen-Spanne:
$1.78
$8.18
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Firmenname
Adverum Biotechnologies Inc
Sektor
Branche
Telefon
(650) 649-1004
Adresse
100 CARDINAL WAY, REDWOOD CITY, CA
Vergleichen Sie ADVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.29 | 94.59M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Hochstufung | Truist | Hold → Buy |
| 2021-07-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Herabstufung | Truist | Buy → Hold |
| 2020-12-16 | Eingeleitet | UBS | Neutral |
| 2020-11-12 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-05 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-09-13 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-06-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2018-11-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Herabstufung | SunTrust | Buy → Hold |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Eingeleitet | SunTrust | Buy |
| 2018-02-15 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Adverum Biotechnologies Inc Aktie (ADVM) Neueste Nachrichten
Has Adverum Biotechnologies Inc. found a price floorTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Will Adverum Biotechnologies Inc. stock deliver consistent dividendsJuly 2025 PreEarnings & Intraday High Probability Alerts - newser.com
What the charts say about Adverum Biotechnologies Inc. today2025 Historical Comparison & Real-Time Stock Movement Alerts - newser.com
Volume spikes in Adverum Biotechnologies Inc. stock – what they meanWeekly Trade Review & Daily Profit Maximizing Tips - newser.com
Detecting price anomalies in Adverum Biotechnologies Inc. with AI2025 Price Action Summary & Safe Swing Trade Setup Alerts - newser.com
Is Adverum Biotechnologies Inc. stock poised for growthMarket Trend Review & Daily Stock Momentum Reports - newser.com
Chart overlay techniques for tracking Adverum Biotechnologies Inc.Weekly Market Summary & Weekly High Potential Stock Alerts - newser.com
Will Adverum Biotechnologies Inc. (AVU0) stock benefit from mergersInflation Watch & Verified Stock Trade Ideas - newser.com
Is Adverum Biotechnologies Inc. stock attractive for growth ETFs2025 Volatility Report & Real-Time Buy Zone Alerts - newser.com
Is it too late to sell Adverum Biotechnologies Inc.Portfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - newser.com
How rising interest rates impact Adverum Biotechnologies Inc. stockQuarterly Trade Summary & Intraday High Probability Alerts - newser.com
Real time social sentiment graph for Adverum Biotechnologies Inc.July 2025 Setups & High Yield Equity Trading Tips - newser.com
How interest rate cuts could boost Adverum Biotechnologies Inc. stockPortfolio Update Report & Weekly High Potential Stock Alerts - newser.com
Eli Lilly To Acquire Adverum Biotechnologies - MSN
RBC Capital Maintains Adverum Biotechnologies (ADVM) Sector Perform Recommendation - MSN
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Mizuho Cuts Price Target on Adverum Biotechnologies to $5.50 From $12, Keeps Outperform Rating - MarketScreener
What drives Adverum Biotechnologies Inc AVU0 stock priceEarnings Revision Updates & Free Grow Wealth With Picks - earlytimes.in
Lilly to purchase Adverum Biotechnologies - Eyes On Eyecare
RBC Raises Price Target on Adverum Biotechnologies to $4 From $3, Keeps Sector Perform, Speculative Risk - MarketScreener
Adverum Biotechnologies (NASDAQ:ADVM) Stock Rating Lowered by Chardan Capital - MarketBeat
With Adverum Biotechnologies Stock Down 6.0% In A Month, How Confident Are You? - Trefis
How Adverum Biotechnologies Inc. (AVU0) stock responds to bond marketMarket Growth Report & Free Community Consensus Stock Picks - fcp.pa.gov.br
With Adverum, Eli Lilly Made A Small Bet That Could Pay Off Big (NYSE:LLY) - Seeking Alpha
Eli Lilly Taps Eyecare Market With Definitive Agreement to Acquire Adverum Biotechnologies - VisionMonday.com
Finanzdaten der Adverum Biotechnologies Inc-Aktie (ADVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):